• Yungjin Pharm’s Nov. 5, 2026, correction disclosed the transfer of Japanese rights to KL1333 to Pharming Technologies under a supplemental agreement.
• Pharming now holds worldwide rights outside South Korea; the agreement also expands the scope of licensed technology.
• The Japanese rights transfer carries additional upfront, milestone and royalty payments, excluded from the existing $3 million upfront and $54 million milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yungjin Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800299), on November 05, 2026, and is solely responsible for the information contained therein.